Karyopharm Therapeutics (KPTI) PT Lowered to $14 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Karyopharm Therapeutics (KPTI) Announces Michael P. Mason as SVP, CFO and Treasurer
February 25, 2019 7:08 AM ESTKaryopharm Therapeutics Inc. (NASDAQ: KPTI) today announced the appointment of Michael P. Mason as Senior Vice President, Chief Financial Officer and Treasurer. In this role, Mr. Mason will be responsible for leading and directing the financial activities of the Company.
Mr. Mason brings to Karyopharm more than 18 years of diversified financial experience in executing financial strategies and leading growth initiatives for life sciences companies. Most recently,... More
